🙌Last week, the Austrian Platform for Personalized Medicine (ÖPPM – Österreichische Plattform für Personalisierte Medizin) held their annual conference, with a focal point of #RareDiseases.
Our founder, Reinhard Pell, had the opportunity to present recent progress on our MCOPS12 research, specifically highlighting our ongoing work on a personalized drug development approach using Antisense Oligonucleotides to treat #MCOPS12.
Personalized medicine, or precision medicine, harnesses your unique genetic makeup to tailor decisions regarding disease prevention, diagnosis, and treatment. It offers an opportunity – especially in the context of rare disease drug development – to transform the traditional “one size fits all” approach to diagnostics and drug therapy into a more individualized and effective approach.
To learn more about personalized medicine, check out: https://www.personalized-medicine.at/
We’re very grateful for the opportunity to participate in this conference and showcase our work at #CureMCOPS12 !
#PrecisionMedicine #Innovation #RareDiseaseResearch #personalizedmedicine #health